Oral Solid Dosage Pharmaceutical Formulation Market Forecast 2032: USD 1349.27 Billion at 7.1% CAGR

Oral Solid Dosage Pharmaceutical Formulation Market to Reach USD 1,349.27 Billion by 2032 at 7.1% CAGR



Oral Solid Dosage Pharmaceutical Formulation Market

ROCKVILLE , MD, UNITED STATES, March 6, 2026 /EINPresswire.com/ -- The global Oral Solid Dosage (OSD) Pharmaceutical Formulation Market is set to surge from USD 779.44 Billion in 2024 to USD 1,349.27 Billion by 2032, at a 7.1% CAGR. Maximize Market Research attributes this growth to the rise of oral GLP-1 therapies and a significant manufacturing reshoring trend in North America. As the FDA's Quality Management Maturity (QMM) standards take hold, the industry is transitioning toward continuous manufacturing and enhanced bioavailability. This evolution solidifies OSD's role as the primary vehicle for global drug delivery, driven by technical innovation and robust domestic supply chain investments.

> Is your pipeline ready for the trillion-dollar shift? Maximize Market Research uncovers the hidden trends redefining global oral solid dosage."
>
> *Maximize Market Research*

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/121388/

Market Dynamics: The Bio-Digital Transformation

The trajectory toward USD 1,349.27 billion is fueled by a structural shift in how medicines are engineered. The industry is rapidly transitioning from traditional batch processing to Continuous Manufacturing (CM) as a primary driver of efficiency. CM platforms

reduce facility footprints by up to 70% and shorten technology transfer timelines, allowing manufacturers to respond instantly to market volatility and drug shortages.

Mirroring this global trend is Gilead Sciences' $32 billion U.S. investment through 2030. In late 2025, the company broke ground on a new 180,000-square-foot Technical Development Center in California. Billed as one of the most AI-enabled hubs in the sector, the facility integrates autonomous robotics and real-time digital monitoring to accelerate the production of next-generation therapies. By adopting Process Analytical Technology (PAT), manufacturers can now monitor quality at the molecular level during production, virtually eliminating the "batch failure" risks that previously hindered global pharmaceutical supply chains.

Key Trends: The Oral Biologic Frontier and 3D Precision

The evolution of oral delivery is defined by the "injectable-to-oral" transition of high-value metabolic therapies. Manufacturers are racing to stabilize large-molecule peptides for gastric absorption. A pivotal shift is occurring in the obesity and diabetes sectors; in early 2026, Novo Nordisk accelerated this trend by committing $506 million to expand its Athlone facility. This investment targets the production of oral GLP-1 analogues, utilizing advanced platforms designed to protect sensitive biologics from digestive enzymes.

Simultaneously, 3D printing (3DP) is moving from laboratory prototypes to clinical reality. Companies like Aprecia Pharmaceuticals lead this charge with proprietary binder-jetting technology creating highly porous, rapidly disintegrating tablets. These "digital pills" allow for precise dose titration and polypill combinations for geriatric populations. By replacing bulk manufacturing with adaptive, layer-by-layer fabrication, the industry is securing a future where medication is tailored to an individual's unique biological profile.

Strategic Segmentation: Precision Formats and Delivery Systems

The structural composition of the OSD market is defined by the continued dominance of Tablets, which currently account for over 68% of the total revenue share. This leadership is sustained by high-speed compression technologies and the relative cost-efficiency of large-scale manufacturing. However, Capsules are the fastest-growing sub-segment, valued for their ability to encapsulate complex, multi-particulate fills and mask bitter active pharmaceutical ingredients (APIs).

A significant shift is also visible in release mechanisms. Immediate-release formulations still hold the majority volume, but Controlled-release and Targeted-delivery systems are expanding at a rapid pace. This growth is driven by the rise of "Fixed-Dose Combinations" (FDCs), which combine multiple APIs into a single unit to improve patient adherence. Furthermore, "Patient-Friendly" formats like Orally Disintegrating Tablets (ODTs) and Gummies are gaining traction in the pediatric and geriatric sectors, where ease of swallowing is a critical factor for therapeutic success.

By Dosage Form

Capsules

Tablets

Powder

Others

By Drug Release Mechanism

Immediate Release

Extended Release

Sustained Release

Controlled Release

Others

By Distribution Channel

Hospital pharmacies

Retail pharmacies

Drug Stores

Online Pharmacy

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/121388/

Regional Analysis: The Shift Toward Localized High-Tech Hubs

The global OSD landscape is being redrawn by a "Local-for-Local" manufacturing mandate. North America remains the dominant revenue engine, commanding a 46.7% market share. This leadership is increasingly defined by the "Research Triangle" hub in North Carolina and Indiana's emerging "Bio-Manufacturing Corridor." The primary driver here is Supply Chain Resiliency; since early 2025, over $13 billion has been committed to domestic OSD facilities to mitigate the risks

of international drug shortages and trade volatility.

Simultaneously, Europe is pivoting toward a "Green OSD" framework. Following the EMA's 2026 Sustainable Development Report, European manufacturers are integrating eco-design into tablet production, focusing on reducing solvent use and carbon-neutral blister packaging. Meanwhile, Asia-Pacific stands as the fastest-growing region, fueled by "Pharma 4.0" initiatives in India and China. These nations are no longer just generic producers; they are evolving into global innovation centers. A notable benchmark is the rapid adoption of AI-enabled predictive maintenance across Indian CDMOs, which has boosted production uptime by 22% and allowed the region to capture a growing share of the high-potency API (HPAPI) market.

Competitive Landscape: The Era of Strategic Consolidation

The OSD market is shifting toward a consolidated ecosystem of "Super-CDMOs." A defining moment is the $16.5 billion acquisition of Catalent by Novo Holdings, finalized in late 2024 and integrated by early 2026. This move has altered capacity dynamics as Novo Nordisk utilizes former Catalent sites to scale its blockbuster oral GLP-1 pipeline, forcing competitors to seek alternative high-capacity partners.

In response, other leaders are aggressively expanding. Lonza reported strong 2025 growth, fueled by its Advanced Synthesis platform and a 2026 focus on small-molecule innovation. Simultaneously, Thermo Fisher Scientific fortified its U.S. presence through a strategic partnership with Sanofi, acquiring a major manufacturing site in New Jersey to meet surging domestic demand. These tier-one players are moving "upstream," engaging with biotech firms during early-phase prototyping to embed proprietary delivery technologies long before commercial scale-up begins.

Oral Solid Dosage Pharmaceutical Formulation Market, Key Players

Takeda Pharmaceutical Company Limited
Merck & Co., Inc., d.b.a
Corealis Pharma Inc.
Astellas Pharma Inc.
CordenPharma International
Bayer AG
Novo Holdings
Thermo Fisher Scientific Inc. (Patheon N.V.)
Lonza
Catalent Inc.
Alcami Corporation
Halo Pharmaceutical Inc.
CordenPharma International
Arnet Pharmaceuticals

Jubilant Life Sciences
Pfizer Inc.
Piramal EnterprisesLtd
Metrics Contract Services
GENVION Corporation
GlaxoSmithKline plc.
CMIC HOLDINGS Co., LTD.
Tower Laboratories Ltd.
PNP Pharmaceuticals Inc.
Confab Laboratories Inc.
Wockhardt Ltd.
Pharma Tech Industries
Thermo Fisher Scientific
Sanofi

Get access to the full description of the report @ https://www.maximizemarketresearch.com/market-report/oral-solid-dosage-pharmaceutical-formulation-market/121388/

Analyst Perspective: The Decade of Macro-Efficiency

The 7.1% CAGR is not merely a growth statistic; it is a reflection of a fundamental re-engineering of the pharmaceutical supply chain. Industry analysts attribute this trillion-dollar trajectory to the convergence of high-potency API (HPAPI) demand and the rapid adoption of AI-driven formulation modeling. By digitizing the trial-and-error phase of drug development, manufacturers are cutting years off R&D timelines. Furthermore, the strategic pivot toward "Resilient Domesticism" in North America ensures that OSD remains the most stable, cost-effective, and patient-compliant vehicle for the next generation of life-saving therapies and complex biological oral delivery.

FAQ’s

What is the projected value of the Oral Solid Dosage market by 2032?
Ans: The global market is expected to reach USD 1,349.27 billion by 2032, expanding at a 7.1% CAGR from its 2024 base of USD 779.44 billion.

Why is North America a critical hub for OSD manufacturing in 2026?
Ans: North America holds a 46.7% market share, driven by "Reshoring" initiatives and the FDA’s Quality Management Maturity (QMM) program, which incentivizes domestic, high-tech production.

How is AI impacting pharmaceutical formulation?
Ans: AI-driven modeling accelerates the development of complex solids, particularly for BCS

Class II and IV molecules, by predicting solubility and stability, significantly reducing R&D timelines.

What are the key growth drivers for oral GLP-1 therapies?
Ans: The transition from injectables to oral solids for obesity and diabetes care is a primary driver, supported by massive infrastructure investments from leaders like Novo Nordisk and Eli Lilly.

Related Reports

Global Tablet Market: https://www.maximizemarketresearch.com/market-report/global-tablet-market/115033/

Personalized Medicine Market: https://www.maximizemarketresearch.com/market-report/global-pharmaceutical-contract-manufacturing-market/65189/

Pharmaceutical Excipients Market: https://www.maximizemarketresearch.com/market-report/global-pharmaceutical-excipients-market/6681/

Generic Drugs Market: https://www.maximizemarketresearch.com/market-report/global-generic-drugs-market/25900/

Top Reports:

Smart Speaker Market https://www.maximizemarketresearch.com/market-report/global-smart-speaker-market/2355/

Lithium-Ion Battery Separator Market https://www.maximizemarketresearch.com/market-report/lithium-ion-battery-separator-market/188833/

Thermos Bottle Market https://www.maximizemarketresearch.com/market-report/thermos-bottle-market/147850/

Agrivoltaics market https://www.maximizemarketresearch.com/market-report/agrivoltaics-market/184243/

Yerba Mate Market https://www.maximizemarketresearch.com/market-report/global-yerba-mate-market/23486/

About Maximize Market Research

Maximize Market Research is a leading global market research and business consulting firm. Our revenue-impact and growth-driven initiatives empower Fortune 500 companies to navigate

complex industrial shifts and secure high-value market dominance.

Domain Focus: Healthcare & Life Sciences

Our research evaluates high-performance pharmaceutical ecosystems through OSD manufacturing innovation and bioavailability enhancement. We analyze the lifecycle economics and continuous manufacturing advancements shaping the global drug delivery landscape from high-potency API (HPAPI) containment to 3D-printed precision dosing and patient-centric formulation strategies.

Lumawant Godage
MAXIMIZE MARKET RESEARCH PVT. LTD.
+ +91 96073 65656
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
X
